Absolute Bioavailability of Fostamatinib (QBR112696)

• Research type

  Research Study

• Full title

  A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers

• IRAS ID

  102816

• Contact name

  Sharan Sidhu

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2012-001214-42

• Research summary

  The purpose of the study is to look at how fostamatinib (the study drug) is taken up by the body when given by mouth and how radiolabelled R406 (produced when fostamatinib is broken down by the body) is taken up by the body when given through an intravenous injection (into a vein). Blood samples will be collected at specific times throughout the study to look at concentrations of the drug in the body.

• REC name

  HSC REC B

• REC reference

  12/NI/0041

• Date of REC Opinion

  26 Mar 2012

• REC opinion

  Favourable Opinion